DUBLIN and MYSTIC, Conn., Aug. 17 /PRNewswire-FirstCall/ —
Amarin Corporation plc (Nasdaq:
AMRN), a clinical-stage biopharmaceutical company with a focus
on cardiovascular disease, today announced that Colin W. Stewart
has been appointed President, Chief Executive Officer (CEO) and a
member of the Company’s Board of Directors effective August 16,
2010. Mr. Stewart will be responsible for driving forward the
Company’s strategy to maximize the value of its lead product,
AMR101, a new drug being studied in Phase 3 clinical trials for the
treatment of high triglycerides. The Company announced last week
that one of its Phase 3 trials, the MARINE trial, completed patient
enrollment and randomization earlier than expected with top-line
results now expected in early 2011.
Mr. Stewart has more than 30 years of experience in executive
management and commercial positions for pharmaceutical companies,
including five years as President and CEO of CollaGenex
Pharmaceuticals, Inc. where he was responsible for the company’s
growth leading to its successful sale in 2008.
In addition, Mr. Stewart served ten years with the ASTA Medica
Group, where he managed several business units in the United States
and internationally. He began his career in sales and marketing for
Winthrop Laboratories, Ltd. in the United Kingdom, and subsequently
held a number of positions of increasing responsibility within the
Sterling-Winthrop Group.
Dr. Declan Doogan, who has been serving as the Company’s Interim
CEO, will continue to support the Company as Chief Medical Officer
providing Amarin access to the majority of his time.
Amarin’s Chairman of the Board, Joseph Zakrzewski, commented,
“We are very excited by the addition of Colin Stewart to the Amarin
team. He brings a wealth of commercial and executive
management experience, which complements the already strong t
‘/>”/>
SOURCE